Physician profile
Keshav Panday
NPI 1710171194
$2,538.95
in general payments reported to CMS, 2019-2025
15 companies · $408 in 2025
The $408 reported for 2025 was more than what 75% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $252 · 2020: $80.04 · 2021: $198 · 2022: $632 · 2023: $524 · 2024: $446 · 2025: $408.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,003 · Education: $375.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,003.11 |
| Education | $374.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $657.37 | 2019-2025 | Tavneos, Uplizna, Evenity |
| Abbvie INC. | $291.73 | 2022-2025 | |
| Janssen Biotech, INC. | $277.36 | 2022-2024 | Tremfya, Simponi Aria |
| Astrazeneca Pharmaceuticals Lp | $259.23 | 2022-2025 | Saphnelo |
| Glaxosmithkline, LLC. | $181.55 | 2022-2025 | Benlysta |
| Pfizer INC. | $169.67 | 2024-2025 | |
| Genzyme Corporation | $109.45 | 2019 | |
| Ucb, INC. | $109.08 | 2020-2025 | Bimzelx |
| E.R. Squibb & Sons, L.L.C. | $108.15 | 2019 | |
| Lilly USA, LLC | $102.61 | 2021 | |
| Janssen Scientific Affairs, LLC | $99.68 | 2022 | |
| Aurinia Pharma U.S., INC. | $95.32 | 2021 | |
| Novartis Pharmaceuticals Corporation | $34.53 | 2025 | |
| Organon LLC | $21.81 | 2025 | Renflexis, Hadlima |
| Bioventus LLC | $21.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keshav Panday listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.